The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 27 March 2007, www.theannals.com, DOI 10.1345/aph.1K051.
 The Annals of Pharmacotherapy: Vol. 41, No. 4, pp. 690-692. DOI 10.1345/aph.1K051
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in The Annals
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drew, R. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drew, R. H

Could Risk Assessment for Non-albicans Candida Improve Empiric Treatment for Invasive Candidiasis?

Richard H Drew, PharmD MS BCPS

Professor of Pharmacy, Campbell University, Buies Creek, NC; Assistant Research Professor (Infectious Diseases), Duke University School of Medicine, Durham, NC

Reprints: Dr. Drew, Box 3306, Duke University Medical Center, Durham, NC 27710, fax 919/681-7494, Richard.Drew{at}Duke.edu

The changing epidemiology of invasive candidiasis, along with concerns for the emergence of drug resistance, necessitates the identification of patients at increased risk of non-albicans Candida (NAC) to optimize selection of antifungal therapy. The major findings of a study regarding the demographic characteristics, costs, and outcomes of nonneutropenic patients with candidemia due to NAC are discussed. Given available treatment options, such risk assessment is most relevant to initial empiric therapy in stable patients without neutropenia who might be candidates for initial therapy with an azole (eg, fluconazole). The study's investigators reinforce the need for timely antifungal therapy for patients with candidemia.

Key Words: Candida albicans, non-albicans Candida, invasive candidiasis

Published Online, March 27, 2007. www.theannals.com, DOI 10.1345/aph.1K051

Related articles in The Annals:

Epidemiology, Risk Factors, and Outcomes of Candida albicans Versus Non-albicans Candidemia in Nonneutropenic Patients
Susan L Davis, Jose A Vazquez, and Peggy S McKinnon
The Annals 2007 41: 568-573. [Abstract] [Full Text]  





homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.